Table of contents:
Video: First Clinical Trial Of COVID-19 Vaccine Begins
First clinical trial of COVID-19 vaccine begins
In Seattle, the first four participants in the study have already received the first dose of the experimental COVID-19 vaccine. The vaccine does not contain viruses, its active ingredient is messenger RNA.
Photo: Tom Wolf / CC BY 2.0 /
On March 16, the first clinical trial of an experimental vaccine against COVID-19 began in Seattle, USA. First, its action will be tested on 45 participants, reports Agence France-Presse.
Four participants have already received the first dose. The experimental vaccine, now called mRNA-1273, was developed by the National Institute of Allergy and Infectious Diseases (NIAID) and the Cambridge biotechnology company Moderna.
Each study participant will receive two doses of the vaccine within six weeks. The interval between vaccination and revaccination is 28 days. Further, the health of each vaccinated person will be monitored for 14 months: with personal visits and by telephone. Scientists will evaluate the immune response of people to the vaccine based on blood tests.
The vaccine contains neither live nor inactivated viruses. Its main active ingredient is the messenger RNA of the virus. After it interacts with the body, the immune system must develop immunity against a protein that helps the coronavirus to attach to cells.
Moderna has previously worked on a vaccine against Middle East respiratory syndrome, which is caused by another member of the coronavirus family. That is why it was possible to prepare the beginning of clinical trials of the first vaccine against COVID-19 in record time.